An oncologist exists to fight cancer in a body that cannot fight it alone, and to\nknow precisely how hard to fight given what the fight will cost the person living\nin that body. Cancer is the disease where the treatment is itself a poison, where\nthe same drug that shrinks a tumor can kill the patient, and where "cure,"\n"control," and "comfort" are three different goals that demand three different\nplans. The oncologist's reason for being is to stage the disease accurately,\nchoose the line of therapy whose benefit exceeds its toxicity for this person,\nand to hold honestly, again and again, the conversation about what the treatment\ncan and cannot do — so the patient spends their time, and their remaining time,\non what they value.
\n","wordCount":127},{"heading":"Core Mission","id":"core-mission","markdown":"Establish the diagnosis and stage, match the patient to the therapy whose\nexpected benefit justifies its toxicity, sequence the lines of treatment as the\ndisease evolves, and keep the goals of care — cure, control, or comfort — honest\nand shared at every step.","html":"Establish the diagnosis and stage, match the patient to the therapy whose\nexpected benefit justifies its toxicity, sequence the lines of treatment as the\ndisease evolves, and keep the goals of care — cure, control, or comfort — honest\nand shared at every step.
\n","wordCount":42},{"heading":"Primary Responsibilities","id":"primary-responsibilities","markdown":"The visible work is prescribing chemotherapy; the actual work is risk-benefit\narithmetic over time and the honest conversation that frames it. An oncologist\nconfirms the tissue diagnosis and molecular profile, stages the cancer, and\ndefines the intent — curative or palliative — before choosing a regimen. They\nselect and sequence systemic therapy (cytotoxic chemotherapy, targeted agents,\nimmunotherapy, hormonal therapy), manage its toxicity, and decide when a line has\nfailed and the next begins. They coordinate the multidisciplinary plan with\nsurgeons and radiation oncologists, monitor response with imaging and markers,\nand recognize the inflection point where more treatment harms more than it helps.\nUnderneath it all is the management of hope and truth simultaneously: telling\npeople the real prognosis without taking away the reason to get up tomorrow.","html":"The visible work is prescribing chemotherapy; the actual work is risk-benefit\narithmetic over time and the honest conversation that frames it. An oncologist\nconfirms the tissue diagnosis and molecular profile, stages the cancer, and\ndefines the intent — curative or palliative — before choosing a regimen. They\nselect and sequence systemic therapy (cytotoxic chemotherapy, targeted agents,\nimmunotherapy, hormonal therapy), manage its toxicity, and decide when a line has\nfailed and the next begins. They coordinate the multidisciplinary plan with\nsurgeons and radiation oncologists, monitor response with imaging and markers,\nand recognize the inflection point where more treatment harms more than it helps.\nUnderneath it all is the management of hope and truth simultaneously: telling\npeople the real prognosis without taking away the reason to get up tomorrow.
\n","wordCount":126},{"heading":"Guiding Principles","id":"guiding-principles","markdown":"- **Stage before you treat.** The stage defines the intent, and the intent\n defines everything. A curable early cancer and an incurable metastatic one with\n the same histology are different diseases requiring opposite tolerances for\n toxicity.\n- **Intent first: cure, control, or comfort.** Name the goal explicitly. Curative\n intent justifies harsh toxicity; palliative intent does not buy weeks at the\n cost of the quality of the time you have.\n- **The benefit must beat the harm for this patient.** A regimen with a 3-month\n median survival gain that costs a frail patient three months of misery is a bad\n trade, however good the trial looked.\n- **Treat the molecular target, not just the organ.** Modern oncology is defined\n by biomarkers — EGFR, ALK, HER2, PD-L1, BRCA, MSI — that turn \"lung cancer\"\n into a dozen different diseases with different drugs.\n- **Lines of therapy are a finite resource; sequence them deliberately.** Each\n line buys time and burns an option; plan the sequence, don't improvise it.\n- **The goals-of-care conversation is treatment.** Discussing what the patient\n values when cure is off the table is not giving up; it is the most consequential\n intervention you offer.","html":"Oncology is multidisciplinary by necessity; no one cures cancer alone. The tumor\nboard is the engine — the medical oncologist, surgeon, radiation oncologist,\nradiologist, and pathologist decide the sequence together, because operating\nbefore chemotherapy or radiating before staging can foreclose a cure. The\npathologist defines the diagnosis behind the diagnosis, including the molecular\nprofile that selects the drug. The palliative-care team is a partner from\ndiagnosis, not a last resort. Oncology nurses administer the toxic regimens and\ncatch the febrile neutropenia at 2 a.m. The recurring friction is the handoff at\nthe goals-of-care inflection point; the discipline is to communicate the intent\nand prognosis explicitly so the whole team rows the same direction.
\n","wordCount":116},{"heading":"Ethics","id":"ethics","markdown":"Oncology lives at the boundary of hope and harm, and that is where its ethics\nconcentrate. Informed consent must be genuine: the patient understands that a\n\"response\" is not a cure, that a median is not a promise, and that the toxicity is\nreal. Truth-telling is a duty even when the truth is a short prognosis, because a\npatient who doesn't know they are dying cannot choose how to spend the time.\nFinancial toxicity is real harm — drugs that cost a fortune for marginal benefit —\nand the honest oncologist names it. The pressure to keep treating, from the\npatient, the family, and the oncologist's own discomfort with stopping, must be\nresisted when treatment no longer serves the patient's goals. And no financial\nincentive — the margin on infused chemotherapy — may shape the recommendation.","html":"Oncology lives at the boundary of hope and harm, and that is where its ethics\nconcentrate. Informed consent must be genuine: the patient understands that a\n"response" is not a cure, that a median is not a promise, and that the toxicity is\nreal. Truth-telling is a duty even when the truth is a short prognosis, because a\npatient who doesn't know they are dying cannot choose how to spend the time.\nFinancial toxicity is real harm — drugs that cost a fortune for marginal benefit —\nand the honest oncologist names it. The pressure to keep treating, from the\npatient, the family, and the oncologist's own discomfort with stopping, must be\nresisted when treatment no longer serves the patient's goals. And no financial\nincentive — the margin on infused chemotherapy — may shape the recommendation.
\n","wordCount":133},{"heading":"Scenarios","id":"scenarios","markdown":"**The frail 78-year-old with metastatic pancreatic cancer.** The reflex is to\noffer combination chemotherapy because it exists. The expert checks performance\nstatus: ECOG 3, mostly bedbound, weight falling. The trial that showed a survival\nbenefit enrolled fitter patients (ECOG 0-1); in this patient the regimen's\ntoxicity will dominate any benefit. The goals-of-care conversation reveals she\nwants to be home and comfortable for a granddaughter's wedding in two months. The\ndecision is single-agent gentle therapy or best supportive care with early\npalliative involvement. Declining the aggressive regimen is the skilled act.\n\n**The biomarker that changes everything.** A 60-year-old never-smoker with\nmetastatic lung adenocarcinoma. The reflex is to start platinum-doublet\nchemotherapy. The expert insists on adequate tissue and molecular profiling\nfirst, even if it delays treatment a week. NGS returns an EGFR exon-19 deletion.\nThe decision flips: a targeted oral inhibitor with a far higher response rate, far\nless toxicity, and longer progression-free survival than chemotherapy. Treating\nthe organ instead of the molecular driver would have given a worse drug for a\nworse outcome.\n\n**Progression on third-line therapy.** A patient with metastatic colorectal\ncancer progresses after three lines, performance status now declining, asking for\n\"whatever's next.\" The expert does not reflexively reach for a fourth line. The\nhonest conversation: the expected benefit of further chemotherapy is now very\nsmall and the toxicity high, and the patient's stated goal is time at home with\nfunction. The decision, made together, is to stop active treatment and transition\nto hospice, with the oncologist staying involved for symptom control. Knowing\nwhen to stop is as much oncology as knowing what to start.","html":"The frail 78-year-old with metastatic pancreatic cancer. The reflex is to\noffer combination chemotherapy because it exists. The expert checks performance\nstatus: ECOG 3, mostly bedbound, weight falling. The trial that showed a survival\nbenefit enrolled fitter patients (ECOG 0-1); in this patient the regimen's\ntoxicity will dominate any benefit. The goals-of-care conversation reveals she\nwants to be home and comfortable for a granddaughter's wedding in two months. The\ndecision is single-agent gentle therapy or best supportive care with early\npalliative involvement. Declining the aggressive regimen is the skilled act.
\nThe biomarker that changes everything. A 60-year-old never-smoker with\nmetastatic lung adenocarcinoma. The reflex is to start platinum-doublet\nchemotherapy. The expert insists on adequate tissue and molecular profiling\nfirst, even if it delays treatment a week. NGS returns an EGFR exon-19 deletion.\nThe decision flips: a targeted oral inhibitor with a far higher response rate, far\nless toxicity, and longer progression-free survival than chemotherapy. Treating\nthe organ instead of the molecular driver would have given a worse drug for a\nworse outcome.
\nProgression on third-line therapy. A patient with metastatic colorectal\ncancer progresses after three lines, performance status now declining, asking for\n"whatever's next." The expert does not reflexively reach for a fourth line. The\nhonest conversation: the expected benefit of further chemotherapy is now very\nsmall and the toxicity high, and the patient's stated goal is time at home with\nfunction. The decision, made together, is to stop active treatment and transition\nto hospice, with the oncologist staying involved for symptom control. Knowing\nwhen to stop is as much oncology as knowing what to start.
\n","wordCount":279},{"heading":"Related Occupations","id":"related-occupations","markdown":"An oncologist is a physician who specialized in cancer, so internal medicine and\nthe diagnostic discipline of the physician are the foundation. The pathologist\ndefines the diagnosis and the molecular profile that selects therapy, making them\nan indispensable partner. The surgeon resects the curable tumor and is half of\nthe multidisciplinary plan. The radiologist stages the disease and measures\nresponse. The pharmacist guards the dosing and interactions of toxic regimens.\nThe palliative-care side of medicine partners from diagnosis through the\nend-of-life transition.","html":"An oncologist is a physician who specialized in cancer, so internal medicine and\nthe diagnostic discipline of the physician are the foundation. The pathologist\ndefines the diagnosis and the molecular profile that selects therapy, making them\nan indispensable partner. The surgeon resects the curable tumor and is half of\nthe multidisciplinary plan. The radiologist stages the disease and measures\nresponse. The pharmacist guards the dosing and interactions of toxic regimens.\nThe palliative-care side of medicine partners from diagnosis through the\nend-of-life transition.
\n","wordCount":85},{"heading":"References","id":"references","markdown":"- *DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology*\n- *The Emperor of All Maladies* — Siddhartha Mukherjee\n- NCCN Clinical Practice Guidelines in Oncology\n- *Harrison's Principles of Internal Medicine* (oncology section)\n- *Being Mortal* — Atul Gawande","html":"